Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1996 1
1997 1
1999 1
2000 2
2001 3
2003 2
2006 1
2007 1
2008 1
2011 2
2012 3
2013 3
2014 1
2015 9
2016 9
2017 4
2018 11
2019 13
2020 15
2021 14
2022 6
2023 6
2024 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 39348971

101 results

Results by year

Filters applied: . Clear all
Page 1
The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC.
Tasoulas J, Lenze NR, Farquhar D, P Schrank T, Shen C, Shazib MA, Singer B, Patel S, Grilley Olson JE, Hayes DN, Gulley ML, Chera BS, Hackman T, Olshan AF, Weiss J, Sheth S. Tasoulas J, et al. Cancer Med. 2021 May;10(10):3231-3239. doi: 10.1002/cam4.3883. Epub 2021 May 2. Cancer Med. 2021. PMID: 33934525 Free PMC article.
Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Zhao X, Zhou Y, Peng G, Wen L, Hong X, Hu Y, Wu B, Liu X, Zhang Z, Xiao G, JingHuang, Ding Q, Yang C, Xiong X, Ma H, Shi L, Yang J, Wei J, Qin Y, Wan C, Zhong Y, Leng Y, Zhang T, Wu G, MinYao, Jia Y, Zhang X, Yang K. Zhao X, et al. Oral Oncol. 2024 Sep;156:106918. doi: 10.1016/j.oraloncology.2024.106918. Epub 2024 Jun 28. Oral Oncol. 2024. PMID: 38943870 Clinical Trial.
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck.
Hanna GJ, O'Neill A, Shin KY, Wong K, Jo VY, Quinn CT, Cutler JM, Flynn M, Lizotte PH, Annino DJ Jr, Goguen LA, Kass JI, Rettig EM, Sethi RKV, Lorch JH, Schoenfeld JD, Margalit DN, Tishler RB, Everett PC, Desai AM, Cavanaugh ME, Paweletz CP, Egloff AM, Uppaluri R, Haddad RI. Hanna GJ, et al. Clin Cancer Res. 2022 Feb 1;28(3):468-478. doi: 10.1158/1078-0432.CCR-21-2635. Epub 2021 Oct 19. Clin Cancer Res. 2022. PMID: 34667025 Free PMC article. Clinical Trial.
101 results